None listed
Conditions
Brief summary
We aim to determine the dose of nicotinamide (NAM) that achieves a serum level of at least 1 mM, and also to assess the effect of nicotinamide on upregulation of neutrophil function and bacterial killing in both patients with bronchiectasis and healthy volunteers. We want to prove if nicotinamide may augment neutrophil function and enhance the killing of respiratory pathogens in patients with bronchiectasis
Interventions
Participants will take oral nicotinamide capsules twice daily in one of the 4 dosage groups for a total duration of 2 weeks:- 1500mg twice daily
2000mg twice daily
2500mg twice daily
3000mg twice daily
compliance will be ensured by capsules count at every follow up visit, blood will be collected for nicotinamide level prior to start of nicotinamide taking and then at every follow up visit.
Sponsors
Dr Conroy Wong, Middlemore Hospital
Study design
Allocation
Non-randomised trial
Intervention model
Other
Primary purpose
Prevention
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
- Male or female aged between 18 to 80 years old - able to provide written consent form - Patients with confirmed bronchiectasis by High resolution CT scan - history of at least one pulmonary exacerbation in the past 12 months - healthy volunteers should be never smoker with no underlying acute or chronic medical conditions and not taking regular medications
Exclusion criteria
- Pregnant or lactating women - patients with significant medical conditions other than bronchiectasis - patients with significant abnormal liver function or with liver cirrhosis - patients with a history of non-adherence with medications
Outcome results
None listed